deferoxamine has been researched along with Optic Nerve Diseases in 11 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
Optic Nerve Diseases: Conditions which produce injury or dysfunction of the second cranial or optic nerve, which is generally considered a component of the central nervous system. Damage to optic nerve fibers may occur at or near their origin in the retina, at the optic disk, or in the nerve, optic chiasm, optic tract, or lateral geniculate nuclei. Clinical manifestations may include decreased visual acuity and contrast sensitivity, impaired color vision, and an afferent pupillary defect.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Eight patients (16 eyes) developed ocular toxicity while undergoing intravenous deferoxamine mesylate (Desferal) chelation therapy for transfusional hemosiderosis." | 3.67 | Deferoxamine (Desferal)-induced toxic retinal pigmentary degeneration and presumed optic neuropathy. ( Jiji, R; Lakhanpal, V; Schocket, SS, 1984) |
| "This drug is the most efficacious for treating iron overload but is associated with ocular toxicity: dose and duration related symptomatic optic neuropathy on the one hand, reversible if treatment stopped, and acute retinal involvement followed by irreversible paucisymptomatic pigmentary changes on the other hand." | 2.44 | [Retinal pigment epithelium--desferal]. ( Roulez, F, 2007) |
| "Deferoxamine is a chelating agent used in the treatment of transfusional iron overload and more recently in the diagnosis and treatment of increased aluminum body stores in chronic renal failure patients." | 1.28 | Irreversible ocular toxicity from single "challenge" dose of deferoxamine. ( Bene, C; Bene, D; Kranias, G; Manzler, A, 1989) |
| "A 4-year-old girl with juvenile chronic myeloid leukemia relapsed after an allogeneic bone marrow transplantation (BMT) and became refractory to conventional chemotherapy." | 1.27 | Deferoxamine (Desferal)-induced ocular toxicity. ( Bashara, S; Goshen, Y; Kaplinsky, C; Stark, B; Yaniv, I; Zaizov, R, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (45.45) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (36.36) | 29.6817 |
| 2010's | 2 (18.18) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ng, WS | 1 |
| Chandra, P | 1 |
| Simon, S | 1 |
| Athanasiov, PA | 1 |
| Jain, R | 1 |
| Raymond, G | 1 |
| Gilhotra, JS | 1 |
| Pelit, A | 1 |
| Haciyakupoglu, G | 1 |
| Zorludemir, S | 1 |
| Mete, U | 1 |
| Daglioglu, K | 1 |
| Kaya, M | 1 |
| Alldredge, CD | 1 |
| Schlieve, CR | 1 |
| Miller, NR | 1 |
| Levin, LA | 1 |
| Roulez, F | 1 |
| Lakhanpal, V | 1 |
| Schocket, SS | 1 |
| Jiji, R | 1 |
| Pinna, A | 1 |
| Corda, L | 1 |
| Carta, F | 1 |
| Hamed, LM | 1 |
| Winward, KE | 1 |
| Glaser, JS | 1 |
| Schatz, NJ | 1 |
| Bene, C | 1 |
| Manzler, A | 1 |
| Bene, D | 1 |
| Kranias, G | 1 |
| Kaplinsky, C | 1 |
| Stark, B | 1 |
| Goshen, Y | 1 |
| Yaniv, I | 1 |
| Bashara, S | 1 |
| Zaizov, R | 1 |
| Orton, RB | 1 |
| de Veber, LL | 1 |
| Sulh, HM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Incidence and Causes of Disc Edema in Patients With Chronic Kidney Disease[NCT00769834] | 0 participants (Actual) | Observational | 2010-01-31 | Withdrawn (stopped due to All investigators have moved to different oranizations) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for deferoxamine and Optic Nerve Diseases
| Article | Year |
|---|---|
[Retinal pigment epithelium--desferal].
Topics: Animals; Deferoxamine; Humans; Injections, Intravenous; Iron Overload; Optic Nerve Diseases; Risk Fa | 2007 |
10 other studies available for deferoxamine and Optic Nerve Diseases
| Article | Year |
|---|---|
Optical coherence tomography in desferrioxamine ocular toxicity: a place in screening and monitoring?
Topics: Aged; Chelating Agents; Deferoxamine; Female; Humans; Optic Nerve Diseases; Retina; Tomography, Opti | 2011 |
Desferrioxamine-related ocular toxicity: a case report.
Topics: Adult; beta-Thalassemia; Deferoxamine; Diagnosis, Differential; Dose-Response Relationship, Drug; El | 2012 |
Preventative effect of deferoxamine on degenerative changes in the optic nerve in experimental retrobulbar haematoma.
Topics: Animals; Deferoxamine; Disease Models, Animal; Hematoma; Iron Chelating Agents; Nerve Degeneration; | 2003 |
Pathophysiology of the optic neuropathy associated with Friedreich ataxia.
Topics: Animals; Animals, Newborn; Anisoles; Cell Death; Cells, Cultured; Chlorides; Deferoxamine; Ferric Co | 2003 |
Deferoxamine (Desferal)-induced toxic retinal pigmentary degeneration and presumed optic neuropathy.
Topics: Aged; Blood Transfusion; Color Perception; Deferoxamine; Female; Hemosiderosis; Humans; Male; Middle | 1984 |
Rapid recovery with oral zinc sulphate in deferoxamine-induced presumed optic neuropathy and hearing loss.
Topics: Administration, Oral; Adult; Astringents; Chelating Agents; Deferoxamine; Female; Hearing Loss, Sens | 2001 |
Optic neuropathy in uremia.
Topics: Adult; Deferoxamine; Female; Humans; Kidney Diseases; Male; Methylprednisolone; Middle Aged; Optic N | 1989 |
Irreversible ocular toxicity from single "challenge" dose of deferoxamine.
Topics: Aluminum; Deferoxamine; Female; Humans; Kidney Failure, Chronic; Macular Edema; Middle Aged; Optic N | 1989 |
Deferoxamine (Desferal)-induced ocular toxicity.
Topics: Blindness; Child, Preschool; Deferoxamine; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL P | 1988 |
Ocular and auditory toxicity of long-term, high-dose subcutaneous deferoxamine therapy.
Topics: Child, Preschool; Deferoxamine; Ear; Eye; Female; Hearing Loss, Sensorineural; Humans; Injections, S | 1985 |